Clinical Trial Update: Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

View source ↗

Summary

This clinical trial update indicates that the expanded access IND for autologous HB-adMSCs to treat systemic lupus erythematosus is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• HB-adMSCs (autologous adipose-derived mesenchymal stem cells)

Snippet

Sponsor: Hope Biosciences Research Foundation | Conditions: System; Lupus Erythematosus | Status: NO_LONGER_AVAILABLE